Abstract:Aging-associated structural alterations and functional decline of the brain microvasculature contribute to the development of cognitive impairment and dementias such as Alzheimer’s disease. The mitochondrial loss and dysfunction appear to play a major role in mechanisms leading to aging-associated changes of the microvasculature, including increased blood brain barrier permeability, vascular rarefication, or decreased branching. SS-31, a small, water-soluble tetra-peptide has been shown to be effective in improving the aging phenotype in healthy, aged rodents as well as in models of neurodegenerative disease. However, the beneficial effects of SS-31 have not been examined on the brain microvascular proteome.We tested the hypothesis that targeting mitochondria with SS-31 rescues aging-associated changes in the brain microvascular proteome.Aged male (> 18 months) C57Bl6/J mice were randomly assigned to the SS-31 treatment (10 mg/kg; i.p.; n = 5) or vehicle saline (n = 5) groups. Mice were treated daily for two weeks. Cerebral blood flow (CBF) was measured using laser speckle imaging at four time points (0, 3, 7, 14 days). Then, cortical microvessels (MVs) containing a mixture of end arterioles, capillaries, and venules, < 70mm, were isolated and used for Orbitrap Eclipse Tribrid mass spectrometry.During the two-week period, baseline CBF was similar between SS-31 and vehicle groups. Bioinformatic analysis showed that treatment with SS-31 resulted in significant differences in protein abundance of cortical MVs vs. vehicle. Twelve percent (107) of the identified 6,266 proteins were mitochondria associated (oxidative phosphorylation, metabolism, the antioxidant defense system) and mitochondrial dynamics were significantly differentially expressed, Our findings suggest that mitochondria are potential therapeutic targets in the aging brain microvasculature, and that changes in the proteome may contribute to the beneficial effects of SS-31 in aging. Our results warrant further study with the inclusion of female animals to investigate the role of sex-differences in the effects of SS-31. This research was supported in part by: IDeA National Resource for Quantitative Proteomics Voucher Program (R24GM137786), Tulane Brain Institute Research Fund Award to IR, NIH HL-148836, NIH AG-063345, NIH AG-075988, the Louisiana Board of Regents Endowed Chairs for Eminent Scholars program to Dr. Busija, P30GM145498, U54 GM104940. The University of Arkansas for Medical Sciences Bioinformatics Core Facility is supported by the Winthrop P. Rockefeller Cancer Institute and National Institutes of Health grant P20GM121293. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins

Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide (SS-31) and nicotinamide mononucleotide (NMN) treatment

The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT)

Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

Targeting mitochondrial dysfunction with elamipretide

Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury

The beneficial effects of SS-31 on aging mice cerebral microvasculature

Treatment with the Mitochondrial‐targeted Antioxidant Peptide SS‐31 Improves Cerebromicrovascular Function in Aged Mice

Elamipretide Attenuates Pyroptosis and Perioperative Neurocognitive Disorders in Aged Mice

Treatment with the mitochondrial antioxidant peptide SS‐31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice

Treatment of aged mice with the mitochondria targeted antioxidative peptide SS‐31 protects against hypertension‐induced cerebral microhemorrhages

Mitochondrial antioxidant elamipretide improves learning and memory impairment induced by chronic sleep deprivation in mice

Abstract P3049: Age-independent Cardiac Protection By Pharmacological Activation Of Beclin-1 During Endotoxemia And Its Association With Energy Metabolic Reprogramming In Myocardium-A Targeted Metabolomics Study

Age‐Independent Cardiac Protection by Pharmacological Activation of Beclin‐1 During Endotoxemia and Its Association with Energy Metabolic Reprograming in Myocardium—A Targeted Metabolomics Study

Dynamic Mitochondrial Proteome Under Polyamines Treatment in Cardiac Aging

SS‐31 and NMN: Two paths to improve metabolism and function in aged hearts

Abstract 017: Mitoprotection Attenuates Myocardial Vascular Impairment and Decreases Coronary Retention of Endothelial Progenitor Cells in Swine Metabolic Syndrome

Spermine and spermidine reversed age-related cardiac deterioration in rats.

Elamipretide (SS-31) Improves Functional Connectivity in Hippocampus and Other Related Regions Following Prolonged Neuroinflammation Induced by Lipopolysaccharide in Aged Rats

Molecular Mechanism of Action of Mitochondrial Therapeutic SS-31 (Elamipretide): Membrane Interactions and Effects on Surface Electrostatics

Resistance training up-regulates Smyd1 expression and inhibits oxidative stress and endoplasmic reticulum stress in the heart of middle-aged mice